Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies - Trial NCT01705106
Access comprehensive clinical trial information for NCT01705106 through Pure Global AI's free database. This Phase 1 trial is sponsored by University of Chicago and is currently Terminated. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 21 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Chicago
Timeline & Enrollment
Phase 1
Aug 29, 2012
Feb 10, 2016
Primary Outcome
AUC of Celecoxib on Combination Therapy (Day 14) and AUC of Celecoxib on Celecoxib Monotherapy(Day 7)
Summary
This clinical trial studies capecitabine and celecoxib in treating patients with solid
 malignancies that are metastatic or cannot be removed by surgery. Drugs used in chemotherapy,
 such as capecitabine, work in different ways to stop the growth of tumor cells, either by
 killing the cells or by stopping them from dividing. Celecoxib may stop the growth of tumor
 cells by blocking some of the enzymes needed for cell growth. Giving capecitabine and
 celecoxib together may be an effective treatment for solid malignancies.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT01705106
Non-Device Trial